Fennec Pharmaceuticals/$FENC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Ticker
$FENC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
32
ISIN
CA31447P1009
Website
FENC Metrics
BasicAdvanced
$232M
-
-$0.53
0.32
-
Price and volume
Market cap
$232M
Beta
0.32
52-week high
$8.72
52-week low
$4.68
Average daily volume
102K
Financial strength
Current ratio
5.134
Quick ratio
4.554
Long term debt to equity
-329.099
Total debt to equity
-333.316
Interest coverage (TTM)
-3.23%
Profitability
EBITDA (TTM)
-11.648
Gross margin (TTM)
90.27%
Net profit margin (TTM)
-46.71%
Operating margin (TTM)
-38.76%
Effective tax rate (TTM)
-2.59%
Revenue per employee (TTM)
$970,000
Management effectiveness
Return on assets (TTM)
-12.96%
Return on equity (TTM)
1,007.54%
Valuation
Price to revenue (TTM)
7.453
Price to book
-39.42
Price to tangible book (TTM)
-39.42
Price to free cash flow (TTM)
-14.061
Free cash flow yield (TTM)
-7.11%
Free cash flow per share (TTM)
-59.74%
Growth
Revenue change (TTM)
-31.23%
Earnings per share change (TTM)
-598.00%
3-year earnings per share growth (CAGR)
-5.81%
10-year earnings per share growth (CAGR)
16.67%
FENC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fennec Pharmaceuticals stock?
Fennec Pharmaceuticals (FENC) has a market cap of $232M as of June 26, 2025.
What is the P/E ratio for Fennec Pharmaceuticals stock?
The price to earnings (P/E) ratio for Fennec Pharmaceuticals (FENC) stock is 0 as of June 26, 2025.
Does Fennec Pharmaceuticals stock pay dividends?
No, Fennec Pharmaceuticals (FENC) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Fennec Pharmaceuticals dividend payment date?
Fennec Pharmaceuticals (FENC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.